Navigation Links
Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
Date:5/2/2011

LONDON, May 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of patent 4,705,370, titled "Further Novel Forms of Interfering RNA Molecules," by the Japanese Patent Office.  The issued patent covers aspects of Silence's platform of novel, short interfering RNA (siRNA) molecules containing 2'-O-Methyl structures known as AtuRNAi.  Silence's AtuRNAi molecules offer important advantages over conventional siRNA molecules including increased stability and yield, lower manufacturing costs and the absence of toxic metabolites.  Several therapeutics incorporating the company's AtuRNAi technology are currently being studied in five ongoing clinical trials conducted by Silence and other industry leaders.

"The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents the latest success in our proactive ongoing intellectual property strategy.  Not only does this milestone offer important protection for our RNAi technology in Japan, but it also provides another critical asset to support our efforts to establish valuable partnerships with leaders in the Japanese pharmaceutical industry," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We believe that this allowance by the Japanese Patent Office coupled with our broad, global protection offered by our core patents will highlight the value of our RNAi therapeutic technology to those Japanese companies with an interest in this exciting area of medicine."

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a global, diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects additional RNAi
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
2. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
3. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
4. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
5. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
6. Silence Therapeutics Appoints New Vice President of Research
7. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Scientists have developed what they believe is the ... made in sheets only three atoms thick. , ... two of these single-layer semiconductor materials can be ... a heterojunction. This result could be the basis ... diodes, or LEDs, and solar technologies. , "Heterojunctions ...
(Date:8/26/2014)... Diego, CA, and Bellingham, WA (PRWEB) August 26, ... and optical engineering, visions for next-generation wearable technology, ... 2015 among numerous highlights at this year’s brighter, ... the San Diego, California, Convention Center. More than ... last week attended conferences, courses, an exhibition, and ...
(Date:8/26/2014)... August 26, 2014 The 20 ambassadors ... ALS (YFALS) community issued the following statement on Facebook ... awareness and driving new funding specifically for ALS research: ... water and some ice would raise all this awareness ... our families, and on behalf of the entire ALS ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4Competition for graphene 2
... Dec. 13, 2011  GenVec, Inc. (Nasdaq: GNVC ... create superior therapeutics and vaccines, today announced that Paul ... his plan to retire as President and Chief Executive ... a successor is named and the CEO transition is ...
... Tarsa Therapeutics today confirmed that it is planning ... Food and Drug Administration (FDA) in the second half ... calcitonin tablet for the treatment of postmenopausal osteoporosis. This follows ... the results from Tarsa,s Phase III ORACAL trial and ...
... - The Pharmabiotic Research Institute (PRI) brings ... probiotics research. It is a unique scientific and regulatory ... that, beyond their traditional food processing applications, probiotics can ... potential. This is why PRI uses the terminology "Pharmabiotics", ...
Cached Biology Technology:GenVec President and Chief Executive Officer Announces Retirement 2GenVec President and Chief Executive Officer Announces Retirement 3Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Targets 2012 NDA Submission for its OSTORA™ Oral Calcitonin 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 2The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 3The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics 4
(Date:8/27/2014)... into doubt the long-standing belief that a deficiency in ... plays a central role in depression. In the journal ... lacking the ability to make serotonin in their brains ... did not show depression-like symptoms. , Donald Kuhn ... Center and Wayne State University School of Medicine note ...
(Date:8/27/2014)... to be associated with outcomes after the repair ... the patient, mechanism of injury, nerve injured, injury ... technique, and repair materials. However, despite numerous studies ... injuries, there is no agreement regarding the independent ... relationship of the predictors has not been quantified. ...
(Date:8/27/2014)... North Carolina State University have found that century-old museum specimens ... common insect pest that can weaken and kill trees ... that scale insect populations increase on oak and maple trees ... pests may also increase with global warming," says Dr. Elsa ... of a paper on the work. , "More scale insects ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Museum specimens, modern cities show how an insect pest will respond to climate change 2
... human brain is not completed at birth. There is ... place in the human brain throughout life, probably for ... that brain structure is under considerable genetic influence [Peper ... into adulthood, involves changes in brain morphology that may ...
... , Mammography continues to be the method of ... because this technique is not as selective or specific ... results for every level of tissue density, alternatives are ... of near-infrared (NIR) light instead of X-rays, is a ...
... MANHATTAN, KAN. -- An award-winning Kansas State University chemistry ... recognizing him for work on microfluidic devices. Chris ... Masao Horiba Award for "Rapid Analysis of Individual T-Lymphocyte ... Wednesday, Oct. 17, during a special ceremony at Kyoto ...
Cached Biology News:Genetic contributions to human brain morphology and intelligence 2Genetic contributions to human brain morphology and intelligence 3Genetic contributions to human brain morphology and intelligence 4Genetic contributions to human brain morphology and intelligence 5Contrast agent trials in swine 2K-State chemistry professor to receive Masao Horiba award 2
... Mount is formulated for covering tissue sections and cell preparations ... end products. , ... Application: ... or AEC that require an aqueous mounting medium, or those ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Solution, pH 9 (x 10) This ... intended for heat-induced target retrieval prior to ... use on formalin-fixed, paraffin-embedded tissue sections mounted ... citrate buffer, pH 6, the use of ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: